1506TiP A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Authors: W. Nassib William Junior, L.H. de Lima Araújo, F.A.F. Da Silva, A.C. Gelatti, E.H.C. Silva, F.J. Silva Melo Cruz, G. De Castro Jr., K.C. Abdalla, M. Zereu, P.R. De Marchi, S. Bandeira Aleixo, S. Cunha Sousa Oliveira, T. Cardoso Motta, R. de Jesus, T.F. Rebelatto
DOI: https://doi.org/10.1016/j.annonc.2023.09.2537
Link: https://www.annalsofoncology.org/article/S0923-7534(23)03374-4/fulltext
Download the study poster presented at the 2023 ESMO Congress here:
